Abstract: Liver metastasis is a key factor impacting the treatment outcomes and survival prognoses of patients with colorectal cancer (CRC). In recent years, immunotherapy has demonstrated revolutionary potential in the treatment of a wide range of solid tumors by strengthening the host's antitumor immune response and has become a mainstream option for the treatment of metastatic or recurrent solid tumors. Immune checkpoint inhibitor-based immunotherapy, in particular, has shown promising advances in safety and efficacy in CRC treatment, especially for deficient mismatch repair (dMMR) CRC. Despite these advances, patients with liver metastases have not seen any improvements in their survival prognoses. In this article, we comprehensively review immunotherapeutic strategies for treating liver metastases from CRC, discuss the efficacy of each strategy, and provide an in-depth discussion of prospective future directions.